What are the guidelines for blood pressure (BP) management in adults with hypertension, including those with comorbid conditions such as diabetes or chronic kidney disease?

Blood Pressure Management Guidelines

Target Blood Pressure Goals

For adults with hypertension, target blood pressure should be <130/80 mmHg in those with diabetes, chronic kidney disease, or known cardiovascular disease, and <140/90 mmHg in those without comorbidities. 1

Standard Risk Patients

• Target BP <140/90 mmHg for all patients with hypertension without comorbidities 1
• This represents a strong recommendation with moderate quality evidence from WHO guidelines 1

High-Risk Patients

• Target systolic BP <130 mmHg for patients with:

  • Known cardiovascular disease (strong recommendation) 1
  • Diabetes mellitus (conditional recommendation) 1, 2
  • Chronic kidney disease (conditional recommendation) 1, 3
  • High cardiovascular risk (10-year ASCVD risk ≥10%) 1, 2

• Target BP <130/80 mmHg specifically recommended by ACC/AHA for these populations 1, 2

Important Caveat on Diastolic Pressure

• Avoid lowering diastolic BP below 60 mmHg, as this may increase cardiovascular events in high-risk patients with treated systolic BP <130 mmHg 1
• Optimal diastolic BP appears to be 70-80 mmHg in high-risk populations 1

---

First-Line Pharmacologic Therapy

Initiate treatment with thiazide/thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers, or long-acting dihydropyridine calcium channel blockers. 1

Drug Class Selection

• All four classes are equally acceptable as first-line monotherapy (strong recommendation, high quality evidence) 1
• Preferred agents include:
  • Thiazide or thiazide-like diuretics 1, 2
  • ACE inhibitors (e.g., lisinopril) 1, 2, 4
  • Angiotensin receptor blockers 1, 2
  • Long-acting dihydropyridine calcium channel blockers (e.g., amlodipine) 1, 2, 5

Combination Therapy

• Single-pill combination therapy is preferred over separate medications to improve adherence 1
• Combine drugs from the three main classes: diuretics, ACE inhibitors/ARBs, and calcium channel blockers 1
• For stage 2 hypertension (BP ≥160/100 mmHg or >20/10 mmHg above target), initiate with two drugs from different classes 1

---

Special Population Considerations

Chronic Kidney Disease

• Target BP <130/80 mmHg for all CKD patients with hypertension 1, 3, 6
• ACE inhibitors are first-line therapy for CKD stage 3 or higher, or stage 1-2 with albuminuria ≥300 mg/day 1, 3, 6
• Use ARBs if ACE inhibitors are not tolerated 1, 3, 6
• Monitor serum creatinine and potassium within 2-4 weeks of starting or increasing ACE inhibitor/ARB dose 3
• Continue ACE inhibitor/ARB unless creatinine rises >30% within 4 weeks 3
• Never combine ACE inhibitor, ARB, and direct renin inhibitor in CKD patients 3, 6
• For kidney transplant recipients, use dihydropyridine calcium channel blockers as first-line therapy 3, 6

Diabetes Mellitus

• Initiate pharmacologic therapy at BP ≥130/80 mmHg 1, 2
• Target BP <130/80 mmHg 1, 2
• Most adults with diabetes and hypertension have 10-year ASCVD risk ≥10%, automatically qualifying them for intensive treatment 1

Older Adults (≥65 Years)

• Treat to the same BP target (<130/80 mmHg) as younger patients if treatment is well tolerated 1, 2
• Initiate therapy cautiously, especially with two drugs, and monitor carefully for orthostatic hypotension 1
• BP-lowering therapy reduces mortality even in frail older adults living independently 1

---

When to Initiate Pharmacologic Treatment

Stage 1 Hypertension (130-139/80-89 mmHg)

• Initiate drug therapy if:
  • Clinical cardiovascular disease present 1, 2
  • 10-year ASCVD risk ≥10% 1, 2
  • Diabetes mellitus 1, 2
  • Chronic kidney disease 1, 2

Stage 2 Hypertension (≥140/90 mmHg)

• Initiate drug therapy in all patients 1, 2
• Treat promptly with careful monitoring and rapid titration until control achieved 1

Elevated BP (120-129/<80 mmHg)

• Lifestyle modifications only 2
• No pharmacologic therapy indicated 2

---

Monitoring and Follow-Up

Initial Titration Phase

• Monthly follow-up after initiating or changing antihypertensive medications until target BP achieved 1, 2
• Assess adherence and therapeutic response at each visit 1

Maintenance Phase

• Follow-up every 3-5 months for patients with controlled BP 1
• Normal BP (<120/80 mmHg): check annually 2
• Elevated BP (120-129/<80 mmHg): check every 3-6 months 2

---

Lifestyle Modifications (Foundation for All Patients)

Implement evidence-based lifestyle interventions for all patients with elevated BP or hypertension. 2

• Sodium restriction to <1500 mg/day 2
• Potassium supplementation 3500-5000 mg/day 2
• Weight loss if overweight/obese 2
• Physical activity 90-150 minutes/week 2
• DASH diet (rich in fruits, vegetables, whole grains, low-fat dairy) can reduce BP by 8-14 mmHg 2

---

Diagnostic Confirmation

Confirm hypertension diagnosis with out-of-office BP measurements before initiating treatment to exclude white coat hypertension 2

• Use home blood pressure monitoring or ambulatory blood pressure monitoring 2
• This prevents unnecessary treatment in patients without true hypertension 2

---

Laboratory Testing

• Obtain screening tests for comorbidities when starting pharmacologic therapy, but only when testing does not delay or impede treatment initiation 1
• Cardiovascular risk stratification can be performed after initiating treatment if feasible and does not delay therapy 1

---

Team-Based Care

• Nonphysician professionals (pharmacists, nurses) can provide pharmacological treatment with proper training, prescribing authority, specific protocols, and physician oversight 1